Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Apr 6;4(2):E132-40.
doi: 10.9778/cmajo.20150036. eCollection 2016 Apr-Jun.

Current use of routinely collected health data to complement randomized controlled trials: a meta-epidemiological survey

Affiliations

Current use of routinely collected health data to complement randomized controlled trials: a meta-epidemiological survey

Lars G Hemkens et al. CMAJ Open. .

Abstract

Background: Studies that use routinely collected health data (RCD studies) are advocated to complement evidence from randomized controlled trials (RCTs) for comparative effectiveness research and to inform health care decisions when RCTs would be unfeasible. We aimed to evaluate the current use of routinely collected health data to complement RCT evidence.

Methods: We searched PubMed for RCD studies published to 2010 that evaluated the comparative effectiveness of medical treatments on mortality using propensity scores. We identified RCTs of the same treatment comparisons and evaluated how frequently the RCD studies analyzed treatments that had not been compared previously in randomized trials. When RCTs did exist, we noted the claimed motivations for each RCD study. We also analyzed the citation impact of the RCD studies.

Results: Of 337 eligible RCD studies identified, 231 (68.5%) analyzed treatments that had already been compared in RCTs. The study investigators rarely claimed that it would be unethical (6/337) or difficult (18/337) to perform RCTs on the same question. Evidence from RCTs was mentioned or cited by authors of 213 RCD studies. The most common motivations for conducting the RCD studies were alleged limited generalizability of trial results to the "real world" (37.6%), evaluation of specific outcomes (31.9%) or specific populations (23.5%), and inconclusive or inconsistent evidence from randomized trials (25.8%). Studies evaluating "real world" effects had the lowest citation impact.

Interpretation: Most of the RCD studies we identified explored comparative treatment effects that had already been investigated in RCTs. The objective of such studies needs to shift more toward answering pivotal questions that are not supported by trial evidence or for which RCTs would be unfeasible.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Selection of RCD studies for the analysis. RCD = routinely collected health data.
Figure 2
Figure 2
The most frequent motivations for performing observational studies using routinely collected health data (RCD studies) claimed by authors who were aware of existing RCT evidence. Each circular area corresponds to one research motivation category; numbers of studies with multiple motivations are depicted in the corresponding overlapping areas (e.g., 11 RCD studies [5% of 213] reported both the assessment of a specific patient population and the study of "real world" effects as motivations). The diagram is schematic; percentages do not correspond to the size of circular areas.

References

    1. Spasoff RA. Epidemiologic methods for health policy. New York: Oxford University Press; 1999.
    1. Developing a protocol for observational comparative effectiveness research: a user's guide. Rockville (MD): Agency for Healthcare Research and Quality; 2013. - PubMed
    1. Cox E, Martin BC, Van Staa T, et al. Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report-Part II. Value Health. 2009;12:1053–61. - PubMed
    1. Howie L, Hirsch B, Locklear T, et al. Assessing the value of patient-generated data to comparative effectiveness research. Health Aff (Millwood) 2014;33:1220–8. - PubMed
    1. Rassen JA, Schneeweiss S. Newly marketed medications present unique challenges for nonrandomized comparative effectiveness analyses. J Comp Eff Res. 2012;1:109–11. - PubMed

LinkOut - more resources